| Sector |
Trading
|
Compare with Sector peers |
| Industry |
Trading
|
Compare with Industry peers |
| Website | http://www.achyuthealthcare.com | |
| Market Cap | 85.47 Cr. | |
| Enterprise Value(EV) | 85.47 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.14 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | 369.70 | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 65.67 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 20.75 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 2.45 | Calculated using Price: 50.80 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.68 Cr. | 16,825,500 Shares |
| FaceValue | 10 | |
| About Achyut Healthcare Ltd. | ||
| The company is engaged in trading of Cenzure, Arpimune, Azathioprine IP, Everomimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Ascorbic Acid Coated Vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Cross Carmalose Sod IP/USP, DI Basic Calcium Phosphate IP, DI Ethyl Phthlate, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products. | ||
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
-2.29% |
| 3 Month |
|
-9.61% |
| 6 Month |
|
-2.78% |
| 1 Year |
|
+3.44% |
| 2 Year |
|
+281.10% |
| 5 Year |
|
|
| 10 Year |
|
| 5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -7.46 | 6.91 | 4.62 | 0.86 | 1.96 | |
| Return on Capital Employed (%) | 7.21 | 9.48 | 5.61 | 2.17 | 2.64 | |
| Return on Assets (%) | -6.33 | 5.58 | 2.88 | 0.77 | 1.83 |
| Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 0 | 0 | 0 | 9 | 15 | 15 | |
| Non Curr. Liab. | 0 | 0 | |||||
| Curr. Liab. | 0 | 0 | 0 | 1 | 1 | 0 | |
| Minority Int. | |||||||
| Equity & Liab. | 0 | 0 | 0 | 10 | 15 | 15 | |
| Non Curr. Assets | 0 | 0 | 2 | 5 | 8 | ||
| Curr. Assets | 0 | 0 | 0 | 8 | 10 | 8 | |
| Misc. Exp. not W/O | |||||||
| Total Assets | 0 | 0 | 0 | 10 | 15 | 15 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 1 | 0 | 0 | 4 | 3 | |
| Other Income | 0 | 0 | 1 | |||
| Total Income | 1 | 0 | 0 | 4 | 3 | |
| Total Expenditure | -1 | 0 | 0 | -4 | -3 | |
| PBIDT | 0 | 0 | 0 | 0 | 0 | |
| Interest | ||||||
| Depreciation | 0 | 0 | ||||
| Taxation | 0 | 0 | 0 | |||
| Exceptional Items | ||||||
| PAT | 0 | 0 | 0 | 0 | 0 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | -7 | 0 | ||
| Cash Fr. Inv. | -2 | -5 | ||||
| Cash Fr. Finan. | 9 | 5 | ||||
| Net Change | 0 | 0 | 0 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 |
|
Fri, 12 Apr 2024
Compliance Certificate - Regulation 7 (3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015. For The Year 01/04/2023 To 31/03/2024 Compliance certificate- Regulation 7(3) of Secutities and Exchange Board of India (LODR) Regulation 2015 for the Financial year ended 31.03.2024 |
|||||||||||||||||||||
|
Thu, 11 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of SEBI DP Regulation for the quarter ended 31st March 2024. |
|||||||||||||||||||||
|
Thu, 11 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Drashti Unadkat Designation: Company Secretary and Compliance Officer EmailId: compliance@achyuthealthcare.com Name of the Chief Financial Officer: Jigen J modi Designation: Managing Director and Cheif Financial Officer EmailId: mahendrazenith@hotmail.com Date: 11/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
| Tue, 16 Apr 2024 |
Closing Above Previous High
|
Making Lower Lows for 2 Days
|
High Increase in 1 Month
|
High Increase in 2 Years
|
Closing Near 20 SMA
|
